We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Reckitt Benckiser Group Plc | LSE:RB. | London | Ordinary Share | GB00B24CGK77 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6,498.00 | 6,502.00 | 6,506.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
11/3/2014 17:58 | Its been reiterated at as a SELL with a 41.00 price target. Me and Sheila have it at a Shaggers SELL with a 29.72 level 4 target Keep an eye on that bubble popping sound Hope this helps | sanks | |
06/2/2014 09:56 | Bid rumours. Hope this helps. | batman9 | |
03/2/2014 12:25 | Matter of time before it breaks the next technical nipples at £42 and £38 Hope this helps | sanks | |
23/1/2014 20:17 | Nomura has a buy and target £50. Citigroup has a buy and target £54. Hope this helps. | batman9 | |
22/1/2014 15:27 | JP Sheila & Sisters have a SELL rating with a £27 target | sanks | |
24/12/2013 12:13 | A merry Christmas to all Reckitt Benckiser holders - I wish you all a prosperous 2014. | batman9 | |
23/10/2013 10:21 | Societe General retains hold but ups target price to £47.50 from £40. Deutsche Bank retains buy and price target £51. Hope this helps. | batman9 | |
22/10/2013 12:48 | Don't worry nobular jockeys...Sheila told me even with these results, they should be a tad or nipple above £29..hence a £31.17 level 4 target is suffice. Matter of time before the bubble pops..its a shaggers market..it'l get a good shagging in good time. Hope this starts to make some sense as it pops nice and slowly Sanksalot......targe | sanks | |
22/10/2013 09:57 | www.rb.com/investors Key dates IMS 22 October 2013 Q4 Full Year Results - 12 February 2014 Q1 IMS - 16 April 2014 Q2 HY Results - 28 July 2014 Q3 IMS - 21 October 2014 | batman9 | |
22/10/2013 09:19 | Wish I'd know date of Quarterly results my system doesn't mention them anyone know how to find the dates? | slogsweep | |
22/10/2013 07:22 | These figures confirm that Reckitts are doing a good deal better than Unilever | steeplejack | |
18/10/2013 16:03 | 7 days and we are above £45 - so much for languishing for a long while below £45 | batman9 | |
11/10/2013 06:19 | Sorry, I should've said 4500 | gbb483 | |
22/9/2013 17:04 | On the other hand this could languish below 4900 for a long while yet. | gbb483 | |
03/9/2013 14:16 | Seems to be gathering pace back towards that £50 area! This could hit that £53-£55 before any real technical fallback. | frontrun | |
28/8/2013 20:03 | Seems Citi along with several other analysts, FORGOT to press the sell button!! Old tricks raising price targets...but then again, fool and his money....plenty of fools in this game. I'm a buyer at £32 agai | agai | |
28/8/2013 15:36 | 8 Aug 2013 Reckitt Benckiser... RB. Citigroup Buy 4,416.00 4,468.00 5,300.00 5,300.00 | miata | |
29/7/2013 12:54 | wow, has taken a hammering today which is a little surprising as results seemed reasonable ! | arja | |
29/7/2013 10:48 | Commenting on these results, Rakesh Kapoor, Chief Executive Officer, said: "I am pleased that our strong focus on Health & Hygiene Powerbrands is working and our improved company growth rates confirm that we are making the right strategic choices. Our Health portfolio has had an excellent 1st half, with Mucinex outperforming a very strong market with excellent innovations such as Sinus-Max and the continued success of our Fast Max line. Durex also delivered an excellent performance supported by creative digital communications across the world, particularly in China which has now become the largest Durex market in the world. In Hygiene, Dettol and Lysol are performing strongly across the world, once again confirming the vast potential of this franchise. Our organizational focus on 16 Powermarkets, such as China, is another critical element of our growth strategy and is enabling us to sustainably outperform our markets. We have systematically increased our brand investment in all our Areas and at the same time invested in enhancing our capabilities to execute and win. I am delighted with the progress we have made with our recent strategic M&As. The excellent early results from Schiff confirm that we have acquired very high quality brands in an exciting VMS category which we firmly believe will deliver sustainable shareholder returns. On Suboxone, we have always been aware of the challenges of operating in a post generic environment. However, we continue to see strong patient and doctor preference for film over tablets and we are very pleased that the film has maintained its volume market share of 69%. We continue to face challenging market conditions. Nonetheless these strong H1 results, our sustained investment behind the equity of our brands, together with excellent progress on the integration of our recent acquisitions, give us confidence that we can achieve full year total revenue growth1at the upper end of +5-6% range (ex RBP) while maintaining adjusted operating margins. | batman9 | |
28/7/2013 20:06 | Monday 29 July Reckitt Benckiser Group (RB.) will kick off the week with results for the second quarter and first half. Recent news: Shares in the consumer goods company have fallen 6% on recent news that US pharmacy benefit manager (PBM) CVS Caremark is to delist its Suboxone film product in favour of generic tablets. Analysts' expectations: "Much remains uncertain but we still think that the market has been too complacent too soon on Suboxone risk," comments Martin Deboo, an analyst at Investec, fearing a "domino theory" of other PBMs delisting the product. He forecasts a 5.4% rise in profit for the second quarter, at the top end of consensus estimates, and a below-consus margin of 19.8% for the first half. Both these figures exclude Reckitt Benckiser's pharmaceutical branch. Deboo has a 'sell' rating on the stock, describing himself as "bearish on valuation". Valuation: Reckitt Benckiser trades on a 2013 EV/EBITDA ration of around 12 times. | spacecake |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions